Cosmos Pharmaceutical Factory' has revenue of more than 100 billion US dollars in 2022, and 56.7 billion US dollars of new crown-related revenue!

On January 31, local time, Pfizer announced its 2022 financial report.

According to the financial report, Pfizer's total revenue in 2022 will be $100.33 billion, a year-on-year increase of 23%, a record high. At the same time, it has become the world's first pharmaceutical enterprise with annual revenue of more than 100 billion US dollars. R&D investment was US$11.428 billion, up 10% year-on-year.

Image source: Pfizer official website

Among them, the new crown vaccine Comirnaty generated $37.8 billion and the new oral drug Paxlovid generated $18.9 billion, totaling $56.7 billion, more than half of its total annual revenue. However, Pfizer expects revenue from coronavirus-related products to decline in 2023, with Comirnaty expected to have revenue of $13.5 billion and Paxlovid at about $8 billion. However, sales may pick up from 2024.

It is worth mentioning that Pfizer showed Paxlovid sales in China in the PPT. Since December 2022, the number of Pfizer supplies of Paxlovid to China has increased significantly, reaching millions of boxes, compared to tens of thousands in the previous 11 months.

Image source: Pfizer official website

Excluding new crown vaccines and oral drugs, full-year revenue was US$43.591 billion, up 2% year-on-year.

The anticoagulant Eliquis (apixaban) continues to sell well, with revenue of $6.5 billion in 2022, up 14%; second, the Pneumococcal vaccine Prevnar family had revenue of $6.3 billion; Sales of Vyndaqel/Vyndamax, which are used to treat rare diseases, reached $2.4 billion.

In addition, Pfizer's $11.6 billion acquisition of Biohaven's new migraine drug Nurtec (Remegipan) has a revenue of $213 million in 2022, which has great potential, and the $5.4 billion acquisition of Oxbryta, a sickle cell disease (SCD) treatment obtained by Global Blood Therapeutics (GBT), also brought $73 million in revenue.

Looking ahead to 2023, Pfizer said that in the next 18 months, Pfizer will launch about 20 new products, including Zavegepant, a nasal spray for acute treatment of migraines, an RSV vaccine PF-06928316, an orally specific JAK3/TEC inhibitor ritlecitinib, and a pentavalent meningococcal vaccine MenABCWY for meningococcal disease. Pfizer set its 2023 revenue guidance at $67 billion to $71 billion; Non-COVID-19 revenue is expected to grow 7%-9% year-over-year.

Source: Pfizer